intellimed has been appointed as the official distributor of Riverain Technologies in Switzerland 🇨🇭
intellimed, a Swiss provider of innovative radiology and AI solutions, is now the official distributor of Riverain Technologies in Switzerland. Riverain is internationally recognized for its ClearRead™ CT platform, which enhances the interpretation of chest images using advanced Clear Visual Intelligence™ technology.
ClearRead CT improves the visibility of pulmonary structures by suppressing bones, blood vessels, and imaging noise, enabling more accurate and efficient detection of lung nodules. The software is compatible with all CT scanners, supports both contrast-enhanced and non-contrast studies, and integrates directly into existing PACS environments without the need for additional viewer applications.
ClearRead™ CT Capabilities
Vessel Suppress: Enhances the visibility of lung tissue by removing overlying structures.
Detect: AI-powered identification of all nodule types for faster, more confident diagnosis.
Compare: Automatically tracks changes in nodules over time to improve follow-up efficiency.
CAC Analysis: Provides data on coronary artery calcification from routine CT scans.
ClearRead CT is FDA-cleared and CE-marked (MDR Class IIa). Clinical studies show improved diagnostic accuracy and reduced interpretation time when used in conjunction with standard CT review.
Purpose for the Swiss Market
The introduction of ClearRead CT in Switzerland supports ongoing efforts to improve early lung cancer detection, optimize CT imaging workflows, and provide actionable cardiovascular risk information from existing thoracic CT scans. With local distribution and support provided by intellimed, Swiss healthcare institutions can evaluate and adopt the solution with integrated training, service, and implementation support.
About Riverain Technologies
Riverain Technologies is a global medical technology company committed to revolutionizing the interpretation of thoracic imaging through AI-powered Clear Visual Intelligence™ solutions. By deploying FDA-cleared, clinically proven deep-learning software that integrates seamlessly into existing PACS workflows, Riverain enables radiologists to “see clearly and decide confidently.” The company’s offerings—including advanced tools for lung nodule detection, vessel suppression, and coronary artery calcification analysis—are designed to improve diagnostic accuracy, accelerate reading times, and support lung screening and cardiothoracic programs worldwide. With a strong network of healthcare partners and a focus on eliminating delayed cardiothoracic disease diagnoses, Riverain Technologies empowers hospitals and imaging centers to adopt cutting-edge AI innovations while maintaining streamlined clinical operations.
https://www.riveraintech.com/